Dr. Evgeny Fink, MD

Dr. Fink practices at GeneSight Lab in Mason, Ohio.

Dr. Fink's NPI, 1306006846, was assigned on June 9, 2008. Dr. Fink graduated from Smolensk State Medical Academy in 1997. Dr. Fink holds New York license 255017.

Dr. Fink's primary practice is GeneSight Lab, at 6000 S Mason-Montgomery Rd, Mason, OH 45040. The practice phone is (513) 701-5000.

Dr. Fink's primary practice is GeneSight Lab in Mason, Ohio. The medical group on file is New York Psychiatric Services, P.C. Dmand AI also links Dr. Fink to 1 more physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fink practices, 3 sites in all. Vendor and product names are available with a free account.

Psychiatry is Dr. Fink's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Fink is board certified in psychiatry by the American Board of Psychiatry and Neurology. Dr. Fink is licensed in New York.

Dmand AI lists adjustment disease, anxiety, bipolar disorder, depression, insomnia, non-alzheimer's dementia (chronic) and schizophrenia among the conditions Dr. Fink treats.

CMS data shows 493 Medicare services from Dr. Fink across 3 procedure codes in 2024, for 82 Medicare patients. Medicare paid $40,732 for them. Every service was in an office.

CMS counts 82 Medicare patients who saw Dr. Fink in 2024. The largest group is 65 to 74, with 26 patients. 75% of them have anxiety, and 75% have depression. 55% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fink's median patient age at 39, with 60% women.

In 2024, Dr. Fink wrote 1,597 Medicare Part D claims for 103 patients. 90% of them were for generic drugs. CMS names the drug for 1,476 of them, across 37 drugs with 11 or more claims each, at $142,216 in total drug cost. In 2023, CMS named 1,678 claims across 44 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Fink for performance year 2024, reported as part of a group. Dr. Fink accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fink as offering telehealth.

Dmand AI links Dr. Fink to 2 clinical trials. Conditions studied include Alzheimer Disease, Stress Disorders, Post-Traumatic and Stress Disorders, Traumatic. Open Payments lists research payments to Dr. Fink that name 2 trials.

CMS Open Payments shows 113 general payments to Dr. Fink from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. Allergan Inc. paid the most, $2,717. It also lists 9 research payments totaling $2,535 from 2016 to 2020, naming 2 clinical trials.

Dr. Fink graduated from Smolensk State Medical Academy in 1997. Dr. Fink is a member of APA.

Dr. Fink is in network with 13 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.